美女免费一级视频在线观看
If you know anything about Charles Barkley, you know he likes to talk a big game. However, when it comes to GLP-1 drugs, the NBA Hall of Famer opts to walk the walk.
He candidly walked consumers through his GLP-1 journey, which started with Eli Lilly’s type 2 diabetes drug Mounjaro. Following shortages of tirzepatide, he joined forces with telehealth platform Ro to raise awareness about taking branded GLP-1 agonists.
Using those two drugs, he lost more than 100 pounds. Now, he’s resumed his weight-loss journey thanks to Lilly’s obesity drug Zepbound.
Through this partnership, Barkley has appeared in a series of ads highlighting challenges patients face as they attempt to access GLP-1 medications.
Ro is also collaborating with Barkley’s recently launched Round Mound Media on projects focused on obesity education and raising awareness of the efficacy of these treatments.
Return to Healthcare Marketing Influencers.
From the August 01, 2025 Issue of MM+M - Medical Marketing and Media